186 related articles for article (PubMed ID: 23496662)
21. Immunotherapies: cause for measured optimism.
Jennings GT; Bachmann MF
Drug Discov Today; 2002 Oct; 7(19):994-6. PubMed ID: 12546915
[No Abstract] [Full Text] [Related]
22. Promises and challenges for the development of Listeria monocytogenes-based immunotherapies.
Brockstedt DG; Dubensky TW
Expert Rev Vaccines; 2008 Sep; 7(7):1069-84. PubMed ID: 18767955
[TBL] [Abstract][Full Text] [Related]
23. Current challenges for the creation of effective vaccines against drugs of abuse.
Moreno AY; Janda KD
Expert Rev Vaccines; 2011 Dec; 10(12):1637-9. PubMed ID: 22085165
[No Abstract] [Full Text] [Related]
24. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers.
Hatsukami DK; Rennard S; Jorenby D; Fiore M; Koopmeiners J; de Vos A; Horwith G; Pentel PR
Clin Pharmacol Ther; 2005 Nov; 78(5):456-67. PubMed ID: 16321612
[TBL] [Abstract][Full Text] [Related]
25. Cancer vaccines.
Chekhun VF
Exp Oncol; 2008 Jun; 30(2):90. PubMed ID: 18680872
[No Abstract] [Full Text] [Related]
26. Ganglioside-based vaccines and anti-idiotype antibodies for active immunotherapy against cancer.
Fernández LE; Alonso DF; Gomez DE; Vázquez AM
Expert Rev Vaccines; 2003 Dec; 2(6):817-23. PubMed ID: 14711364
[TBL] [Abstract][Full Text] [Related]
27. [Expecting the antinicotine vaccine].
Didilescu C
Pneumologia; 2009; 58(3):177-8. PubMed ID: 19817315
[TBL] [Abstract][Full Text] [Related]
28. Immunology-15th European Congress. 8-12 June 2002, Rhodes, Greece.
Contrafouris Y
IDrugs; 2003 Jul; 6(7):647-9. PubMed ID: 12906013
[No Abstract] [Full Text] [Related]
29. Letter from the editor: field of vaccines and immunotherapeutics.
Ellis RW; Riedmann EM
Hum Vaccin Immunother; 2013 Jan; 9(1):1-2. PubMed ID: 23442580
[No Abstract] [Full Text] [Related]
30. Anticytotoxic T lymphocyte-associated antigen 4 treatment--can melanoma be cured at the expense of autoimmune disorders?
Lejeune FJ
Melanoma Res; 2006 Oct; 16(5):377-8. PubMed ID: 17013085
[No Abstract] [Full Text] [Related]
31. [Cancer immunotherapy].
Vakkila J; Pihkala U
Duodecim; 1999; 115(7):785-94. PubMed ID: 11859512
[No Abstract] [Full Text] [Related]
32. Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy.
Waldmann TA; Dubois S; Tagaya Y
Immunity; 2001 Feb; 14(2):105-10. PubMed ID: 11239443
[No Abstract] [Full Text] [Related]
33. On immunotherapies and cancer vaccination protocols: a mathematical modelling approach.
Joshi B; Wang X; Banerjee S; Tian H; Matzavinos A; Chaplain MA
J Theor Biol; 2009 Aug; 259(4):820-7. PubMed ID: 19446568
[TBL] [Abstract][Full Text] [Related]
34. Vaccines against non-communicable diseases.
Röhn TA; Bachmann MF
Curr Opin Immunol; 2010 Jun; 22(3):391-6. PubMed ID: 20338740
[TBL] [Abstract][Full Text] [Related]
35. Introduction to The Renaissance of Cancer Immunotherapy.
Finn OJ; Schuler G
Ann N Y Acad Sci; 2013 May; 1284():v-vii. PubMed ID: 23651200
[No Abstract] [Full Text] [Related]
36. Cancer vaccines: pessimism in check.
Timmerman JM; Levy R
Nat Med; 2004 Dec; 10(12):1279; author reply 1279-80. PubMed ID: 15682512
[No Abstract] [Full Text] [Related]
37. Cancer vaccines: toward the next revolution in cancer therapy.
Emens LA
Int Rev Immunol; 2006; 25(5-6):259-68. PubMed ID: 17169776
[No Abstract] [Full Text] [Related]
38. T cell targeted immunotherapy for autoimmune disease.
Lee E; Sinha AA
Autoimmunity; 2005 Dec; 38(8):577-96. PubMed ID: 16390811
[TBL] [Abstract][Full Text] [Related]
39. Poxviruses as vectors for cancer immunotherapy.
Kwak H; Hörig H; Kaufman HL
Curr Opin Drug Discov Devel; 2003 Mar; 6(2):161-8. PubMed ID: 12669450
[TBL] [Abstract][Full Text] [Related]
40. DNA vaccines for autoimmune diseases.
Garren H
Expert Rev Vaccines; 2009 Sep; 8(9):1195-203. PubMed ID: 19722893
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
